CN101028282B - Use of low-molecular weight phaeophytin polyose sulfate in preparation of medicine for treating kidney disease - Google Patents
Use of low-molecular weight phaeophytin polyose sulfate in preparation of medicine for treating kidney disease Download PDFInfo
- Publication number
- CN101028282B CN101028282B CN2007100643133A CN200710064313A CN101028282B CN 101028282 B CN101028282 B CN 101028282B CN 2007100643133 A CN2007100643133 A CN 2007100643133A CN 200710064313 A CN200710064313 A CN 200710064313A CN 101028282 B CN101028282 B CN 101028282B
- Authority
- CN
- China
- Prior art keywords
- molecular
- low
- weight
- algal polysaccharide
- polysaccharide sulfate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims description 14
- 208000017169 kidney disease Diseases 0.000 title claims description 13
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 title abstract description 3
- 201000008383 nephritis Diseases 0.000 claims abstract description 13
- 206010029164 Nephrotic syndrome Diseases 0.000 claims abstract description 4
- 208000001647 Renal Insufficiency Diseases 0.000 claims abstract description 4
- 201000006370 kidney failure Diseases 0.000 claims abstract description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 111
- 239000005017 polysaccharide Substances 0.000 claims description 111
- -1 polysaccharide sulfate Chemical class 0.000 claims description 92
- 150000004676 glycans Chemical class 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 14
- 241000199919 Phaeophyceae Species 0.000 claims description 7
- 241000195493 Cryptophyta Species 0.000 claims description 6
- 241000227647 Fucus vesiculosus Species 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 241000737023 Zebrasoma flavescens Species 0.000 claims description 5
- 206010069440 Henoch-Schonlein purpura nephritis Diseases 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 229920001542 oligosaccharide Polymers 0.000 claims description 3
- 150000002482 oligosaccharides Chemical class 0.000 claims description 3
- 206010037596 Pyelonephritis Diseases 0.000 claims description 2
- 241000264279 Sargassum fusiforme Species 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 206010018366 Glomerulonephritis acute Diseases 0.000 claims 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims 1
- 231100000851 acute glomerulonephritis Toxicity 0.000 claims 1
- 210000003928 nasal cavity Anatomy 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 20
- 208000009928 nephrosis Diseases 0.000 abstract 1
- 231100001027 nephrosis Toxicity 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 66
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 54
- 210000003734 kidney Anatomy 0.000 description 41
- 210000002966 serum Anatomy 0.000 description 35
- 238000000034 method Methods 0.000 description 34
- 210000002700 urine Anatomy 0.000 description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 33
- 229940109239 creatinine Drugs 0.000 description 27
- 210000004369 blood Anatomy 0.000 description 24
- 239000008280 blood Substances 0.000 description 24
- 239000000243 solution Substances 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 16
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 description 16
- 239000000126 substance Substances 0.000 description 14
- 208000020832 chronic kidney disease Diseases 0.000 description 13
- 229960003657 dexamethasone acetate Drugs 0.000 description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 12
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 12
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 11
- 238000000465 moulding Methods 0.000 description 11
- 230000001575 pathological effect Effects 0.000 description 11
- 210000005239 tubule Anatomy 0.000 description 11
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 10
- 238000006731 degradation reaction Methods 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 229930024421 Adenine Natural products 0.000 description 9
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 9
- 102000009027 Albumins Human genes 0.000 description 9
- 108010088751 Albumins Proteins 0.000 description 9
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 229960000643 adenine Drugs 0.000 description 9
- 230000015556 catabolic process Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 9
- 239000013641 positive control Substances 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 8
- 229920000855 Fucoidan Polymers 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 229920000615 alginic acid Polymers 0.000 description 8
- 235000010443 alginic acid Nutrition 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000000108 ultra-filtration Methods 0.000 description 8
- 238000012869 ethanol precipitation Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 230000002503 metabolic effect Effects 0.000 description 7
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical group C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 6
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000011668 ascorbic acid Substances 0.000 description 6
- 229960005070 ascorbic acid Drugs 0.000 description 6
- 235000010323 ascorbic acid Nutrition 0.000 description 6
- 238000000502 dialysis Methods 0.000 description 6
- 229960004756 ethanol Drugs 0.000 description 6
- 229930182830 galactose Natural products 0.000 description 6
- 210000000244 kidney pelvis Anatomy 0.000 description 6
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 6
- 210000004279 orbit Anatomy 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 241000908922 Chorda filum Species 0.000 description 5
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 5
- 229920001543 Laminarin Polymers 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 5
- 102000007562 Serum Albumin Human genes 0.000 description 5
- 108010071390 Serum Albumin Proteins 0.000 description 5
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 5
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 5
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 230000035619 diuresis Effects 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 238000007710 freezing Methods 0.000 description 5
- 230000008014 freezing Effects 0.000 description 5
- DBTMGCOVALSLOR-VPNXCSTESA-N laminarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)C(O[C@H]2[C@@H]([C@@H](CO)OC(O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-VPNXCSTESA-N 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000012109 statistical procedure Methods 0.000 description 5
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 4
- 241000195474 Sargassum Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 238000004043 dyeing Methods 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000002980 postoperative effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 206010001580 Albuminuria Diseases 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 3
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000005227 gel permeation chromatography Methods 0.000 description 3
- 238000004192 high performance gel permeation chromatography Methods 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000512259 Ascophyllum nodosum Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241001474374 Blennius Species 0.000 description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 241000195480 Fucus Species 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 2
- 241001260874 Sargassum horneri Species 0.000 description 2
- 241001355994 Sargassum phyllocystum Species 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 239000000385 dialysis solution Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 230000007515 enzymatic degradation Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 229960002003 hydrochlorothiazide Drugs 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 210000000885 nephron Anatomy 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000005085 renal fascia Anatomy 0.000 description 2
- 239000011435 rock Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical class CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000980780 Cladosiphon okamuranus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 241000946389 Ecklonia kurome Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000022461 Glomerular disease Diseases 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000000067 Pyelectasis Diseases 0.000 description 1
- 108010056079 Subtilisins Proteins 0.000 description 1
- 102000005158 Subtilisins Human genes 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- MYCFWRWSRJKNGB-UHFFFAOYSA-N [NH+]1=CC=CC=C1.[Cl-].CCCCCCCCCCCCCCCC Chemical compound [NH+]1=CC=CC=C1.[Cl-].CCCCCCCCCCCCCCCC MYCFWRWSRJKNGB-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000002681 cryosurgery Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000003311 flocculating effect Effects 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 231100000852 glomerular disease Toxicity 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 210000004276 hyalin Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000000874 microwave-assisted extraction Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- FQXBMKZVLSACGS-UHFFFAOYSA-N n,n-dimethylmethanamine;hexadecane;hydrobromide Chemical compound Br.CN(C)C.CCCCCCCCCCCCCCCC FQXBMKZVLSACGS-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- BPATYLCKLFEYHC-UHFFFAOYSA-N oxolead;hydrate Chemical compound O.[Pb]=O BPATYLCKLFEYHC-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940023569 palmate Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 229940011964 pentobarbital sodium 30 mg Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Description
Group | Dosage (mg/kg) | Number of animals (only) | Glomerule diameter (lattice number) | Messangial cell number (number) |
Blank | 10 | 8.62±0.96 | 87.03±8.34 | |
The model contrast | 8 | △△△11.12±0.83 | △△△116.10±15.37 | |
Sample A | 200 | 8 | 9.71±1.05 ** | 109.99±38.97 |
Sample A | 100 | 8 | 10.75±0.88 | 119.24±14.39 |
Sample 1 | 200 | 8 | 10.35±1.09 | 117.30±16.80 |
Dexamethasone acetate | 0.1 | 8 | 9.76±0.68 ** | 105.79±9.27 |
Group | Dosage (mg/kg) | Number of animals (only) | The swelling degree ( ±s) | Suppression ratio (%) | P value (vs model group) |
Model | \ | 10 | 45.58±28.24 | ||
Sample 1 | 300 | 8 | 30.92±22.25 | 36.36 | >0.05 |
Sample B | 150 | 9 | 26.30±12.08 | 45.86 | <0.01 |
Sample B | 300 | 9 | 23.10±4.43 | 52.45 | <0.01 |
Dexamethasone | 0.1 | 9 | 15.96±11.20 | 67.15 | <0.01 |
Group | Dosage (mg/kg) | Number of animals (only) | C 3 | C 3 | 1gG | 1gM |
Normally | \ | 8 | 35.63±4.94 | 24.59±10.27 | 27.33±12.92 | 81.78±40.44 |
Model | \ | 8 | 51.79±26.71 | 30.92±7.07· | 36.89±8.60·· | 103.33±20.26· |
Sample 1 | 300 | 8 | 54.96±29.49· | 28.58±5.51 | 37.43±10.14 | 92.75±25.58 |
Sample B | 150 | 7 | 37.23±24.92 | 23.43±11.10 * | 37.96±6.19 | 112.12±29.74 |
Sample B | 300 | 8 | 35.01±18.04 * | 16.02±10.56 ** | 30.21±15.43 * | 80.23±28.15 * |
Dexamethasone | 0.1 | 9 | 30.03±7.85 ** | 17.95±9.82 ** | 31.08±7.37 * | 79.32±26.80 * |
Claims (9)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100643133A CN101028282B (en) | 2007-03-12 | 2007-03-12 | Use of low-molecular weight phaeophytin polyose sulfate in preparation of medicine for treating kidney disease |
PCT/CN2008/000850 WO2008122214A1 (en) | 2007-03-12 | 2008-04-25 | The use of low molecular weight fucoidan in preparing of medicine for treating kidney diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100643133A CN101028282B (en) | 2007-03-12 | 2007-03-12 | Use of low-molecular weight phaeophytin polyose sulfate in preparation of medicine for treating kidney disease |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101028282A CN101028282A (en) | 2007-09-05 |
CN101028282B true CN101028282B (en) | 2012-05-30 |
Family
ID=38713934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007100643133A Active CN101028282B (en) | 2007-03-12 | 2007-03-12 | Use of low-molecular weight phaeophytin polyose sulfate in preparation of medicine for treating kidney disease |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN101028282B (en) |
WO (1) | WO2008122214A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101306014B (en) * | 2008-04-03 | 2012-03-14 | 北京世纪博康医药科技有限公司 | Use of brown algae polysaccharide sulfuric acid ester of low molecular weight in preparing medicine for treating diabetic nephropathy |
CN102532332B (en) * | 2011-09-09 | 2014-07-09 | 山东洁晶集团股份有限公司 | Method for extracting and preparing low molecular weight fucoidin from marine brown algae |
CN107899005B (en) * | 2017-11-20 | 2021-02-26 | 北京颐方生物科技有限公司 | Composition containing fucoidan, tablet and application thereof |
CN111494407A (en) * | 2020-01-08 | 2020-08-07 | 南京市儿童医院 | Use of trehalose in the preparation of a medicament for alleviating conditions associated with acute renal injury induced by ischemia reperfusion |
CN115671118B (en) * | 2021-07-22 | 2024-02-27 | 海糖(江苏)生物医药科技有限公司 | Application of brown alginate oligosaccharides |
CN113632987A (en) * | 2021-08-12 | 2021-11-12 | 威海威仕泰医疗科技有限公司 | Kidney disease non-total nutrient special medical food based on fucoidin and preparation method thereof |
CN114984037B (en) * | 2022-08-04 | 2022-10-04 | 山东第一医科大学附属省立医院(山东省立医院) | Low-molecular-weight algin and preparation method and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1129109A (en) * | 1995-12-16 | 1996-08-21 | 中国科学院海洋研究所 | Medicine of alginic polysaccharide sulfate for treatment of nephrasthenia and angiopathy and preparation method thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1206591A (en) * | 1998-05-08 | 1999-02-03 | 毕爱芳 | Medicine for brown algae polyose sulfate for curing glomerular disease |
CN1069523C (en) * | 1998-10-14 | 2001-08-15 | 中国科学院海洋研究所 | Application of alginic polysaccharide sulfate in preparation of medicine for treating renal failure |
CN1267457C (en) * | 2004-10-18 | 2006-08-02 | 中国科学院海洋研究所 | Method for preparing low molecular weight seaweed polysaccharide sulfate |
-
2007
- 2007-03-12 CN CN2007100643133A patent/CN101028282B/en active Active
-
2008
- 2008-04-25 WO PCT/CN2008/000850 patent/WO2008122214A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1129109A (en) * | 1995-12-16 | 1996-08-21 | 中国科学院海洋研究所 | Medicine of alginic polysaccharide sulfate for treatment of nephrasthenia and angiopathy and preparation method thereof |
Non-Patent Citations (2)
Title |
---|
吴茜茜等.功能性低分子量岩藻多糖的研究进展.生物学杂志23 3.2006,23(3),4-7. |
吴茜茜等.功能性低分子量岩藻多糖的研究进展.生物学杂志23 3.2006,23(3),4-7. * |
Also Published As
Publication number | Publication date |
---|---|
CN101028282A (en) | 2007-09-05 |
WO2008122214A1 (en) | 2008-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101028282B (en) | Use of low-molecular weight phaeophytin polyose sulfate in preparation of medicine for treating kidney disease | |
Saghir et al. | Structure characterization and carboxymethylation of arabinoxylan isolated from Ispaghula (Plantago ovata) seed husk | |
CN1842341B (en) | Active fraction having anti-cancer and anti-metastic activity isolated from leaves and stems of ginseng | |
KR100674672B1 (en) | Chitosan-containing polysaccharide, process for producing the same and use thereof | |
CN1985847B (en) | Use of low molecular weight brown algae polyose fulfate in preparing medicine for treating cardiac and cerebral vascular diseases | |
CN1985846B (en) | Use of brown algae polyose sulfate in preparing medicine for treating cardic and cerebral vascular diseases | |
Yu et al. | Immunomodulatory activities of sulfated Cyclocarya paliurus polysaccharides with different degrees of substitution on mouse spleen lymphocytes | |
CN105985451B (en) | A kind of Radix Angelicae Sinensis acidity polysaccharide component and its extracting method and application | |
Li et al. | Structural characterization of novel comb-like branched α-D-glucan from Arca inflata and its immunoregulatory activities in vitro and in vivo | |
CN102234336A (en) | Fucoidan-galactosan sulfate, extracting, separating, and purifying method thereof, and application thereof | |
Inngjerdingen et al. | Chemical and biological characterization of polysaccharides from wild and cultivated roots of Vernonia kotschyana | |
CN101306014B (en) | Use of brown algae polysaccharide sulfuric acid ester of low molecular weight in preparing medicine for treating diabetic nephropathy | |
Ng et al. | Chemical structures, extraction and analysis technologies, and bioactivities of edible fungal polysaccharides from Poria cocos: An updated review | |
CN101011412A (en) | Usage of low-molecular-weight algal polysaccharide sulfate in preparation of medicament for treating hepatic disease | |
EP0849280B1 (en) | Fucans with low molecular weight having anticoagulant, antithrombinic and antithrombotic activity | |
CN102319256A (en) | Application of porphyra polysaccharide in preparing treatment medicament or prevention health-care product of kidney diseases | |
WO2023036203A1 (en) | Cs-4 fermented mycelium heteropolysaccharide, preparation method therefor and use thereof | |
CN110950976A (en) | Glucosamine hyaluronate and application | |
CN110218262A (en) | Application of low-sulfated heteroglycan rich in glucuronic acid and derived from brown algae in preparation of medicines for treating type 2 diabetes | |
CN101011411A (en) | Usage of algal polysaccharide sulfate in preparation of medicament for treating hepatic disease | |
Lin et al. | Extraction, structure and bioactivities of polysaccharides from Sanghuangporus spp.: A review | |
US9737558B2 (en) | Peyer's patch activator | |
KR102258569B1 (en) | Sulfated polygulonic acid polysaccharide or pharmaceutical salt thereof, preparation method therefor and use thereof | |
CN102204946B (en) | Chinese lobelia polysaccharide extracted from Chinese lobelia and application thereof | |
CN110063964A (en) | Application and preparation method thereof of the fucosan as PCSK9 inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: WEIHAI SHIJI BOKANG SEAWEED CO., LTD. Free format text: FORMER OWNER: BEIJING SHIJI BOKANG PHARMACEUTICAL SCI. + TECH. CO., LTD. Effective date: 20150708 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150708 Address after: 264200, Xinqiao Road, Qiaotou town, Weihai, Shandong, China Patentee after: Weihai century beaucamp seaweed Co. Address before: 100070 Beijing City, Fengtai District science and Technology Park of Fengtai Haiying Road No. 9, building 3 203 Jintang Patentee before: Beijing Shiji Bokang Pharmaceutical Sci. & Tech. Co., Ltd. |
|
DD01 | Delivery of document by public notice |
Addressee: Weihai century beaucamp seaweed Co. Document name: Notification of Passing Examination on Formalities |
|
CP02 | Change in the address of a patent holder |
Address after: 264317 Rongcheng Industrial Park 1518, Weihai City, Shandong Province Patentee after: Weihai century beaucamp seaweed Co. Address before: 264200 Xinqiao Road, China-Korea (Qiaotou) Industrial Park, Qiaotou Town, Jing District, Weihai City, Shandong Province Patentee before: Weihai century beaucamp seaweed Co. |
|
CP02 | Change in the address of a patent holder | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200703 Address after: Room 3936, Sino German Eco Park Innovation and entrepreneurship center, 172 Taibaishan Road, Huangdao District, Qingdao City, Shandong Province Patentee after: Qingdao very ho Marine Technology Co., Ltd Address before: No. 1518, Rongcheng Industrial Park, Weihai City, Shandong Province Patentee before: Weihai century beaucamp seaweed Co. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210119 Address after: Room 4259, innovation and entrepreneurship center, Sino German ecological park, 172 Taibaishan Road, Huangdao District, Qingdao City, Shandong Province, 266500 Patentee after: Qingdao Shishu Ocean Technology Co.,Ltd. Address before: Room 3936, innovation and entrepreneurship center, Sino German ecological park, 172 Taibaishan Road, Huangdao District, Qingdao City, Shandong Province, 266500 Patentee before: Qingdao very ho Marine Technology Co., Ltd |